Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
31 Julho 2023 - 5:01PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today announced that
Pascal Touchon, President and Chief Executive Officer, will
participate at the Canaccord Genuity 43rd Annual Growth Conference
on Wednesday, August 9, 2023 at 1:00 p.m. PDT / 4:00 p.m. EDT.
A live webcast of the presentation will be available by visiting
the Investors and Media section of atarabio.com. An archived replay
of the webcast will be available on the Company's website for 30
days following the live presentation.
About Atara Biotherapeutics, Inc. Atara is harnessing the
natural power of the immune system to develop off-the-shelf cell
therapies for difficult-to-treat cancers and autoimmune conditions,
including multiple sclerosis, that can be rapidly delivered to
patients within days. With cutting-edge science and differentiated
approach, Atara is the first company in the world to receive
regulatory approval of an allogeneic T-cell immunotherapy. Our
advanced and versatile Epstein-Barr virus (EBV) T-cell platform
does not require T-cell receptor or HLA gene editing and forms the
basis of a diverse portfolio of investigational therapies that
target EBV, the root cause of certain diseases, in addition to
next-generation AlloCAR-Ts designed for best-in-class opportunities
across a broad range of non-EBV-associated liquid and solid tumors.
Atara is headquartered in Southern California. For more
information, visit atarabio.com and follow @Atarabio on Twitter and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230728481682/en/
INVESTORS & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024